Table 3.

Overall and progression-free survival (intention-to-treat population)

	Intensive pathway		Non-intensive pathway		Overall
	Zoledronic acid (n=555)	Clodronic acid (n=556)	Zoledronic acid (n=426)	Clodronic acid (n=423)	Zoledronic acid (n=981)	Clodronic acid (n=979)
Overall survival	NR (61·0–NR)	62·5 (53·5–NR)	33·5 (29·5–36·5)	29·5 (25·5–34·0)	50·0 (46·0–60·5)	44·5 (42·0–51·5)
Progression-free survival	25·0 (23·5–28·5)	25·0 (22·5–27·0)	13·5 (12·0–14·0)	12·5 (11·5–13·5)	19·5 (18·0–21·0)	17·5 (16·5–19·5)

Data are median months (95% CI). NR=not reached.